Search - tctmd.com

Displaying 681 - 700 of 975

Sort: Relevancy | Date

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

News Daily News

Benefit-Based Approach to Statins Pinpoints One in Six Patients Eligible for Therapy

Michael O'Riordan

October 25, 2018

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

October 22, 2018

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

News Daily News

More Research Supports Use of Aspirin Alone to Prevent VTE After Knee Replacement Surgery

October 18, 2018

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

News Daily News

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

October 16, 2018

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

August 28, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

August 25, 2018

Hospital Readmissions at 30 Days Declining for Stroke Patients

News Daily News

Hospital Readmissions at 30 Days Declining for Stroke Patients

Michael O'Riordan

August 20, 2018

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

August 15, 2018

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

Peer Pressure May Push Physicians to Do Better at Prescribing Statins

News Daily News

Peer Pressure May Push Physicians to Do Better at Prescribing Statins

July 30, 2018

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

News Daily News

Real-world Analysis Suggests Apixaban Is Safest of the NOACs, Even for Patients With A-fib

July 06, 2018

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

July 02, 2018

New Estimates of Bleeding Risks May Help CVD Prevention

News Daily News

New Estimates of Bleeding Risks May Help CVD Prevention

June 27, 2018

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

News Daily News

All-Cause Death Not Increased With Febuxostat Among Medicare Patients With Gout

June 19, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.